Possible role of plasminogen activator inhibitor 2 in the prevention of the metastasis of gastric cancer tissues

Thromb Res. 1992 Mar 15;65(6):709-19. doi: 10.1016/0049-3848(92)90110-v.

Abstract

The concentrations of urinary type plasminogen activator (u-PA), plasminogen activator inhibitor 1 (PAI-1), and PAI-2 were measured in gastric cancer tissues and adjacent healthy mucosal tissues. Levels of u-PA, PAI-1 and PAI-2 were higher in cancer than in control tissues. PAI-1 levels were higher together with the progression of cancer however there were no differences in u-PA or PAI-2 levels. Tumors with higher PAI-1 and lower PAI-2 levels tend to metastasize to remote lymph nodes. When the numbers of involved lymph nodes were analyzed, tumors with the large number of metastatic lymph nodes showed higher PAI-1 and lower PAI-2 level. No difference was shown in u-PA levels among these groups. These tendencies were more significant in patients with progressed gastric cancer. These results suggest that tumor with higher PAI-2 levels tend to localize or have less tendency to metastasize to lymph nodes. On the other hand PAI-1 was generally higher in tumor with invasion into nearby tissue or with nodal metastasis.

MeSH terms

  • Enzyme-Linked Immunosorbent Assay
  • Humans
  • Immunohistochemistry
  • Lymphatic Metastasis
  • Neoplasm Invasiveness
  • Neoplasm Metastasis / prevention & control
  • Plasminogen Inactivators / metabolism*
  • Stomach Neoplasms / metabolism
  • Stomach Neoplasms / pathology*
  • Urokinase-Type Plasminogen Activator / metabolism

Substances

  • Plasminogen Inactivators
  • Urokinase-Type Plasminogen Activator